Please check your internet connection and try again.
# Lorazepam (representative benzodiazepine)
## Overview
Lorazepam is a benzodiazepine with anxiolytic, sedative, hypnotic, amnestic, and anticonvulsant properties. It acts by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, resulting in central nervous system depression.
## Primary Indications
* Anxiety disorders
* Insomnia due to anxiety
* Status epilepticus
* Premedication for medical or surgical procedures to induce sedation and anxiolysis
## Adult Dosing
* **Anxiety Disorders:** 1 to 2 mg orally two to three times daily. Maximum dose: 10 mg/day.
* **Insomnia due to Anxiety:** 1 to 2 mg orally at bedtime.
* **Status Epilepticus:** 4 mg intravenous (IV) or intramuscular (IM) initially. May repeat 4 mg every 5 to 10 minutes if seizure persists. Maximum dose: 8 mg in a 12-hour period.
* **Premedication:**
* Oral: 2 to 3 mg one to two hours before surgery.
* IM: 0.05 mg/kg (max 4 mg) 2 hours before surgery.
* IV: 2 mg (or 0.04 mg/kg) administered slowly 15 to 20 minutes before surgery.
Dosing for other indications should be individualized.
## Pediatric Dosing
Dosing in pediatric patients should be individualized and based on age, weight, and clinical response. Due to potential for paradoxical reactions and respiratory depression, caution is advised.
* **Status Epilepticus:**
* Ages 10-18 years: 0.05 mg/kg IV (max 4 mg per dose). May repeat every 5-10 minutes as needed. (Dose based on APA guidelines, but local protocol should be consulted).
* Neonates and infants: Generally avoided due to increased risk of respiratory depression and apnea. If used, very low doses and careful monitoring are required.
There is limited established dosing for other indications in pediatrics; consult specialized resources.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary.
* **Renal Impairment:** Use with caution; dose reduction may be necessary.
* **Elderly:** Initiate at the lower end of the usual adult dose range (e.g., 0.5 mg orally twice daily) and titrate slowly as needed, due to increased sensitivity and risk of sedation, ataxia, and falls.
## Contraindications
* Known hypersensitivity to lorazepam, other benzodiazepines, or any component of the formulation.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis (relative contraindication).
* Sleep apnea.
## Adverse Effects
* **Common:** Sedation, drowsiness, dizziness, fatigue, unsteadiness, weakness, confusion.
* **Less Common:** Amnesia, ataxia, depression, slurred speech, blurred vision, gastrointestinal upset, paradoxical excitement or aggression.
* **Serious:** Respiratory depression, apnea, hypotension, paradoxical reactions (especially in children and elderly), dependence, withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives, antihistamines):** Additive CNS depression, increasing risk of sedation, respiratory depression, and death. Co-administration with opioids requires extreme caution and should be reserved for patients for whom alternative treatment options are inadequate. Use the lowest effective doses for the shortest possible duration.
* **CYP3A4 Inhibitors/Inducers:** Lorazepam is primarily metabolized by glucuronidation, not CYP enzymes, so interactions are less common compared to other benzodiazepines. However, some agents may affect metabolism or protein binding.
* **Valproic Acid:** May increase lorazepam plasma concentrations and risk of toxicity.
## Monitoring
* **Efficacy:** Assess reduction in anxiety, improvement in sleep, cessation of seizures, or desired level of sedation.
* **Safety:** Monitor for excessive sedation, respiratory rate and depth, blood pressure, and signs of CNS depression.
* **Dependence/Withdrawal:** Assess for signs of physical dependence and withdrawal symptoms (e.g., anxiety, insomnia, irritability, tremor, nausea, seizures) particularly upon dose reduction or discontinuation.
* **Cognitive Function:** Assess for amnesia or cognitive impairment, especially with higher doses or IV administration.
## Clinical Pearls
* Lorazepam has a relatively long half-life, but its active metabolite is minimal.
* For IV administration, inject slowly to minimize risk of respiratory depression and hypotension.
* Abrupt discontinuation can lead to withdrawal symptoms; gradual tapering is essential.
* Paradoxical reactions (e.g., excitement, aggression) can occur, particularly in children and the elderly.
* Avoid alcohol and other CNS depressants.
* Use in pregnancy should be carefully considered due to potential risks to the fetus, especially in the third trimester (risk of sedation and withdrawal symptoms in the neonate).
***
*Please verify this information against the current official prescribing information for lorazepam as protocols and recommendations can change.*
